ADXN (Addex Therapeutics Ltd) stock: $3.40, $5.8M market cap, $2.1M cash, $3.7M EV, $31.2M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
Dipraglurant
Preclinical · Active
Target mGlu5
Partnerships Sinntaxis AB: option and collaboration agreement (Apr 30, 2025) for exclusive license to IP covering mGlu5 inhibitors in brain injury recovery plus research collaboration; economics not disclosed
Indications- Post-stroke/TBI recovery (Stage not disclosed)
Status note Lead development compound per this filing. Further in vivo testing in stroke models ongoing; Phase 2a start planned subject to funding or securing a development partner (no date stated).
ADX71149
Phase 2 · Active Modality: small molecule (orally active PAM)
Target mGlu2
Partnerships Janssen (terminated): development terminated Jul 22, 2024; partnership agreement terminated Apr 17, 2025 with program and IP returned to Addex
Indications- Indication under evaluation (Stage not disclosed)
Status note Janssen terminated development (Jul 22, 2024) after Phase 2 did not support continued development; partnership terminated Apr 17, 2025 and program returned to Addex. Company currently evaluating future development.
GABAB PAM (Indivior-selected compound)
Preclinical · Active
Target GABAB
Partnerships Indivior: worldwide rights licensed; Indivior selected compound Aug 27, 2024 and completed IND-enabling studies May 12, 2025; Indivior responsible for all development, manufacture and commercialization; milestones and royalties in USD (amounts not disclosed)
Indications- Substance use disorder (SUD) (Preclinical)
Status note IND-enabling studies completed by Indivior May 12, 2025. All future development undertaken by Indivior.
GABAB PAM (Addex chronic cough program)
Discovery · Active
Target GABAB
Partnerships n/a (independent program; rights retained under Indivior agreement)
Indications- Chronic cough (Stage not disclosed)
Status note Selected compound; in late clinical candidate selection phase. IND-enabling studies planned subject to securing funding or a development partner (no date stated).
M4 PAM (Neurosterix program)
Phase 1 · Active
Target M4
Partnerships Neurosterix (spin-out; Addex holds 20% equity interest and received CHF 5.0M cash on divestiture Apr 2, 2024; Addex does not control development)
Status note Lead program of spin-out Neurosterix, advancing through Phase 1 clinical studies. Addex holds a 20% equity interest only; not an Addex-operated pipeline program.
Per-asset detail extracted from the 20-F filed 2026-05-15. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.